Tesamorelin + Ipamorelin Research Guide: Combined GHRH + GHRP Vial
This combination vial pairs Tesamorelin (long-acting GHRH analog) with Ipamorelin (selective GHRP) for synergistic GH-axis research.
What is the combination?
A dual-peptide research vial pairing Tesamorelin — a stabilized 44-amino-acid GHRH analog — with Ipamorelin, a selective pentapeptide GHRP. The two peptides target the pituitary somatotroph via independent receptors.
Component mechanisms
Tesamorelin — trans-3-hexenoyl-modified GHRH(1-44) analog. Long-acting GHRH-receptor agonist that drives sustained GH secretion.
Ipamorelin — pentapeptide GHSR-1a agonist. Produces a clean GH pulse without cortisol or prolactin elevation.
Sourcing & purity
Research-grade material should be ≥99% pure by HPLC with peptide content confirmed via mass spectrometry. Redline Bio material ships with batch documentation; independent third-party COAs are published on the lab reports page as testing returns.
Compliance reminder
Sold and distributed for laboratory research use only. Not approved by the FDA for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations.
Frequently asked questions
What is in the vial?
Each 15 mg vial contains 10 mg Tesamorelin and 5 mg Ipamorelin. The 18 mg vial contains 12 mg Tesamorelin and 6 mg Ipamorelin.
Why combine GHRH + GHRP?
The two act on separate receptors (GHRH-R and GHSR-1a). Combined stimulation produces a synergistic GH pulse substantially larger than either agent alone — a well-established pattern in GH-secretion research.